S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals September 2008
This guidance provides recommendations for dose selection for carcinogenicity studies of human pharmaceuticals. The guidance is intended to aid sponsors in selecting appropriate doses for rodent carcinogenicity studies.
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.